AbbVie Pledges $100 Billion to Boost US Healthcare and Innovation, Expands TrumpRx Program

AbbVie has entered into a strategic agreement with the Trump administration to enhance medication affordability and sustain pharmaceutical innovation in the US. The company has pledged $100 billion towards US-centric research, development, and manufacturing over the next decade, aiming to expand the TrumpRx program to provide medications directly to millions of Americans. AbbVie recognizes the complexities of the US healthcare system and aims to address them through this initiative.